 |
 |
|
|
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
 Featured MNV Articles:
| Implied PTH Analyst Target Price: $53By Dividend Channel Staff, Friday, February 16, 8:22 AM ET
Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. For the Invesco Dorsey Wright Healthcare Momentum ETF (NASDAQ:PTH), we found that the implied analyst target price for the ETF based upon its underlying holdings is $53.23 per unit. With PTH trading at a recent price near $44.56 per unit, that means that analysts see 19.46% upside for this ETF looking through to the average analyst targets of the underlying holdings. Three of PTH's underlying holdings with notable upside to their analyst target prices are C4 Therapeutics Inc (NASDAQ:CCCC), Quanterix Corp (NASDAQ:QTRX), and BridgeBio Pharma Inc (NASDAQ:BBIO). Although CCCC has traded at a recent price of $7.90/share, the average analyst target is 89.87% higher at $15.00/share. Similarly, QTRX has 23.52% upside from the recent share price of $26.23 if the average analyst target price of $32.40/share is reached, and analysts on average are expecting BBIO to reach a target price of $46.92/share, which is 19.59% above the recent price of $39.23. Below is a twelve month price history chart comparing the stock performance of CCCC, QTRX, and BBIO:
Combined, CCCC, QTRX, and BBIO represent 5.13% of the Invesco Dorsey Wright Healthcare Momentum ETF. Below is a summary table of the current analyst target prices discussed above:
Are analysts justified in these targets, or overly optimistic about where these stocks will be trading 12 months from now? Do the analysts have a valid justification for their targets, or are they behind the curve on recent company and industry developments? A high price target relative to a stock's trading price can reflect optimism about the future, but can also be a precursor to target price downgrades if the targets were a relic of the past. These are questions that require further investor research. The average analyst target price data upon which this article was based, is courtesy of data provided by Zacks Investment Research via Quandl.com.
This Article's Word Cloud:
Analyst
BBIO
Below
BridgeBio
CCCC
Corp
Dorsey
ETFs
FREEGet
Healthcare
Invesco
Momentum
Pharma
QTRX
Quanterix
Target
Therapeutics
Upside
With
Wright
Zacks
about
above
analyst
analysts
average
background
based
border
bottom
color
data
font
from
have
hctblstyle
holdings
latest
mdash
price
recent
report
research
share
target
targets
that
trading
underlying
upside
|
Play Video:
The Importance of ETFs
Free Email Alerts By Stock:
Start slideshow: